Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Medizinische Hochschule Hannover · Moscow City Oncology Hospital №62 · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
645
total citations
- FWCI
- 37.84
- Percentile
- 100%
- References
- 28
Citations per year
Authors
17- RGRalf GutzmerCorresponding
Medizinische Hochschule Hannover
- DSDaniil Stroyakovskiy
Moscow City Oncology Hospital №62
- HGHelen Gogas
Laiko General Hospital of Athens, National and Kapodistrian University of Athens
- CRCaroline Robert
Université Paris-Saclay, Institut Gustave Roussy
- KDKarl D. Lewis
University of Colorado Denver, University of Colorado Cancer Center
Topics & keywords
Topics
Keywords
- Atezolizumab
- Vemurafenib
- Medicine
- Placebo
- Internal medicine
- Adverse effect
- Hazard ratio
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.